Schering-Plough Splits With Chinese Joint Venture To Complete Global Organon Merger
This article was originally published in The Pink Sheet Daily
Executive Summary
Merged company plans expansion throughout China and the Asia-Pacific region.
You may also be interested in...
Schering-Plough China To Acquire Shanghai Schering-Plough
The equity transfer of Shanghai Schering-Plough's 45 percent has gone into the final stages of price quotation. According to sources at share-owner Shanghai Pharmaceutical (Group) which is selling its stake, the quotation system still maintains its list price of 66.33 million yuan. Except for original shareholder Schering-Plough China, no other company has submitted application of acceptance; thus, there will be no surprises if Schering-Plough China takes over Shanghai Schering-Plough. So far the equity transaction has started and will be completed at the beginning of July. Shanghai Schering-Plough will then become a wholly-owned subsidiary of a foreign pharmaceutical firm. (Click here for more - Chinese Language)
Schering-Plough Makes Its Move, Snapping Up Organon For $14.4 Billion
After much talk of a major acquisition, Schering buys the Organon pharmaceutical and animal health business of Akzo Nobel.
Bayer Schering Partners With Polish Biotech Firm To Provide Recombinant Insulin To China's Exploding Diabetics Population
Bayer's antidiabetes drug Glucobay (acarbose), an alpha-glucosidase inhibitor, is already one of the company's strongest products in China.